According to pg 25-26 of the PDF for Zoloft (found using google/ www.zoloft.com)... these are some of the passages I found including pregnancy (also I believe some of this is included in the papers that come with medicatino when you pick it up)...

"ZOLOFT (sertraline hydrochloride)
should be used during pregnancy only if the potential benefit justifies the potential risk to the
fetus.
Pregnancy-Nonteratogenic Effects–Neonates exposed to Zoloft and other SSRIs or SNRIs, late
in the third trimester have developed complications requiring prolonged hospitalization,
respiratory support, and tube feeding. These findings are based on postmarketing reports. Such
complications can arise immediately upon delivery. Reported clinical findings have included
respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty,
vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and
constant crying. These features are consistent with either a direct toxic effect of SSRIs and
SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the
clinical picture is consistent with serotonin syndrome (see WARNINGS).
Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary
hypertension of the newborn (PPHN). PPHN occurs in 1-2 per 1,000 live births in the general
population and is associated with substantial neonatal morbidity and mortality. In a retrospective
case-control study of 377 women whose infants were born with PPHN and 836 women whose
infants were born healthy, the risk for developing PPHN was approximately six-fold higher for
infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been
exposed to antidepressants during pregnancy. There is currently no corroborative evidence
regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that
has investigated the potential risk. The study did not include enough cases with exposure to
individual SSRIs to determine if all SSRIs posed similar levels of PPHN risk.
When treating a pregnant woman with ZOLOFT during the third trimester, the physician should
carefully consider both the potential risks and benefits of treatment (see DOSAGE AND
26
ADMINISTRATION). Physicians should note that in a prospective longitudinal study of 201
women with a history of major depression who were euthymic in the context of antidepressant
therapy at the beginning of pregnancy, women who discontinued antidepressant medication
during pregnancy were more likely to experience a relapse of major depression than women who
continued antidepressant medication.
Labor and Delivery–The effect of ZOLOFT on labor and delivery in humans is unknown.
Nursing Mothers–It is not known whether, and if so in what amount, sertraline or its
metabolites are excreted in human milk. Because many drugs are excreted in human milk,
caution should be exercised when ZOLOFT is administered to a nursing woman."